AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01968460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Description: Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
Study NCT01968460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01968460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Description: Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
Study NCT04363372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx-4DP0004
Description: MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
Study NCT04363372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be identical in appearance to active product.
Study NCT01135589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: i.v.
Study NCT03644433 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single layer closure
Description: Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
Study NCT03644433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double layer closure after resection uterine scar
Description: Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
Study NCT00559507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Study NCT00559507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02723825 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Closed reduction
Description: Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
Study NCT02723825 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open reduction
Description: Open reduction and internal fixation
Study NCT02723825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction
Description: Open reduction and internal fixation
Study NCT01323205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
Study NCT01323205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
Study NCT01323205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule (s) orally twice daily with a meal for 4 weeks.
Study NCT01323205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Description: Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
Study NCT01412970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: volume loading
Description: volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
Study NCT00610142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
Study NCT00610142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortison 1% cream
Description: twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
Study NCT00280995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Study NCT00280995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Study NCT00280995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
Study NCT00280995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Study NCT01976780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Study NCT01976780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine
Study NCT01976780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Study NCT05489601 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Description: Oxycodone in 5mg increments up to a maximum of 10mg
Study NCT02623738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Study NCT02623738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution low
Study NCT02623738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution high
Study NCT02623738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Study NCT01882907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin 50mg bid for 16 weeks
Study NCT01882907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg bid for 16 weeks
Study NCT04674631 — intervention group
Intervention type: OTHER
Intervention: The effect of neuropathic pain on quality of life, depression and sleep quality
Description: The effect of neuropathic pain on quality of life, depression and sleep quality
Study NCT01396005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
Study NCT01396005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
Study NCT04013061 — intervention group
Intervention type: OTHER
Intervention: Pluridisciplinary consultation
Description: Pharmacist-anesthesiologist team will be present during the anesthetic consultation
Study NCT01396005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
Study NCT02527044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Description: An FFR will be performed pre-operative to the CABG procedure
Study NCT02527044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Description: An FFR will be performed pre-operative to the CABG procedure
Study NCT00444678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m2, IV every two weeks
Study NCT00444678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, IV, q 2 weeks
Study NCT00444678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2500 mg, po bid x 7 days every two weeks
Study NCT01250496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: 75 mg of intravenous aminophylline
Study NCT01250496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Study NCT03007810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study NCT02653768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Exercise Program
Description: STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit
Study NCT03007810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study NCT04495205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF under non-eugenol containing periodontal pack
Description: Platelet Rich Fibrin under non-eugenol containing periodontal pack
Study NCT04495205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-eugenol containing periodontal pack
Description: Non-eugenol containing periodontal pack after gingival depigmentation
Study NCT02735135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRSOFT DUO for 1 day
Description: The patient is placed on an AIRSOFT DUO mattress for 1 day.
Study NCT02653768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis Education
Description: The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
Study NCT04036409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Control of Systolic Blood Pressure (SBP)
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
Study NCT04036409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of Systolic Blood Pressure (SBP)
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study NCT02343471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g whey protein
Study NCT02343471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 20 g whey protein
Study NCT00521846 — intervention group
Intervention type: DEVICE
Intervention: Biomet Explor Modular Radial Head Replacement
Description: As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
Study NCT04117776 — intervention group
Intervention type: OTHER
Intervention: Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)
Description: 3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
Study NCT04117776 — intervention group
Intervention type: OTHER
Intervention: Skin microbiological sampling (wash with mild soap)
Description: 3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
Study NCT01496885 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This was an observational study and no study drug was administered.
Study NCT01404299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: - Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
Study NCT01404299 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: - No intervention, except monthly home visits
Study NCT00003793 — intervention group
Intervention type: GENETIC
Intervention: clonality analysis
Study NCT00003793 — intervention group
Intervention type: GENETIC
Intervention: microsatellite instability analysis
Study NCT00003793 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT03164382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
Study NCT03164382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 200Mg Tab
Description: Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
Study NCT00133523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated influenza virus vaccine, trivalent
Description: Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
Study NCT00133523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline administered as an intramuscular injection.
Study NCT00133523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
Study NCT00133523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
Study NCT00133523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal allantoic fluid administered annually as an internasal spray.
Study NCT03833830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography angiography (OCTA)
Description: There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group >20 injections and shortterm treatment group \< 5 injections).
Study NCT06423079 — intervention group
Intervention type: PROCEDURE
Intervention: Siepser knots
Description: Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation
Study NCT04703894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES 'CARDIFF'
Description: AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study NCT02083380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 640mg
Description: Active, loose combination
Study NCT02083380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 960mg
Description: Active, loose combination
Study NCT02083380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 1440mg
Description: Active, loose combination
Study NCT01164085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ketorolac
Description: 4mg of intravitreal ketorolac
Study NCT04514679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Healthy Lifestyles Program
Description: Regular group visits with a health coach in addition to routine dietician and clinician visits, reviewing successes and challenges from the previous session as well as data collected through self-monitoring
Study NCT04514679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Obesity Medicine Program
Description: A tailored approach to obesity care for patients including individual dietician and health coach visits as appropriate.
Study NCT01964066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography balloon dilatation
Study NCT01964066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography balloon dilatation
Study NCT01964066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Description: Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
Study NCT01964066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Premedication
Description: For premedication used trimeperidine 2%-1ml intravenously.
Study NCT00522795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPX with cisplatin and radiation
Description: weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
Study NCT02690623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric hospitalist program
Description: In-house hospitalists available at all hours
Study NCT02690623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Pediatric Inpatient Services
Description: Inpatient care by general pediatrics faculty
Study NCT04276584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive expiratory pressure
Description: Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
Study NCT04276584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speaking loudly during about 3 minutes
Description: A specified swedish text
Study NCT01044966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITV DepoCyt + Temozolomide
Description: Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
Study NCT03783520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Description: Er,Cr:YSGG Laser is used for disinfection of the root canals.
Study NCT03783520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: Sodium hypochlorite is used for disinfection of the root canals
Study NCT02771132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-hr IMPower empowerment self defense course
Description: The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack.
Study NCT02771132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-hr Source of Strength for boys
Description: The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
Study NCT02771132 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life-skills course
Description: A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
Study NCT03771365 — intervention group
Intervention type: PROCEDURE
Intervention: Standard-PCNL
Description: percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
Study NCT03771365 — intervention group
Intervention type: PROCEDURE
Intervention: Mini-PCNL
Description: percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
Study NCT03771365 — intervention group
Intervention type: PROCEDURE
Intervention: SMP
Description: percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone